Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A
Haemophilia
.
2020 Sep;26(5):e232-e235.
doi: 10.1111/hae.14047.
Epub 2020 Jun 4.
Authors
Mark P Smith
1
,
Jeremy Rupon
2
,
Yasser Wali
3
,
Hala Rimawi
4
,
Joan Korth-Bradley
2
,
Lynne Smith
2
,
Pablo Rendo
2
Affiliations
1
Canterbury Health Laboratories, Christchurch, New Zealand.
2
Pfizer Inc, Collegeville, PA, USA.
3
Sultan Qaboos University, Muscat, Oman.
4
King Abdullah University Hospital, Irbid, Jordan.
PMID:
32497363
DOI:
10.1111/hae.14047
No abstract available
Publication types
Letter
MeSH terms
Adolescent
Child
Child, Preschool
Factor VIII / therapeutic use*
Hemophilia A / drug therapy*
Humans
Infant
Infant, Newborn
Substances
recombinant factor VIII SQ
Factor VIII
Grants and funding
Pfizer Inc